Stocks

What to watch: USFDA nod to drug may strengthen Zydus Cadila

| Updated on April 25, 2019 Published on April 26, 2019

Zydus Cadila facility

Zydus Cadila (Cadila Healthcare) has received final approval from the USFDA to market Leflunomide tablets USP (US RLD - Arava Tablets), 10 mg and 20 mg. The drugs will be manufactured at its formulations manufacturing facility at Baddi. This medication is used to treat rheumatoid arthritis. The group now has 263 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04. Shareholders will watch further developments.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on April 26, 2019
This article is closed for comments.
Please Email the Editor